The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

Kazuhiko Usui1, Takuma Yokoyama2, Akira Kishoara, Yosibaki Mori3, Yuichiro Takeda4, Hiro Ishida1, Nobuko Kusano1, Kazuma Kishi1, Utae Katsushita5, Tomohito Kuwako2, Hiromi Aono3, Yusuke Shikama3, Koichi Minato1, Hideazu Matsushita1, Koji Uemura1, Yasuo Ohashi6, Hideo Kunitoh7

1 NTT Medical Center, 2Kumamoto University Hospital, 3Kobe City General Medical Center, 4Tottori University Medical Center, 5National Cancer Center Research Institute, 6Kagoshima University Hospital, 7National Health Organization Hiroshima National Hospital.

Abstract

This clinical trial was funded and supported by AstraZeneca.

Clinical Trial Number: UMIN000023248

This clinical trial is funded and supported by AstraZeneca.

Introduction

Plasma sampling schedule

31

Consort diagram

N=122

N=122

N=122

N=64

N=57

N=57

Osimertinib

Osimertinib

Osimertinib

Osimertinib

Osimertinib

Other

Other

Other

Other

Other

Baseline

6month

12month

Treatment after failure of the first EGFR TKI

Mutation status at disease progression, T790M was detected in 15 (78.9%) of 19 patients with T790M detection in plasma. In 15% of the patients who acquired resistance to previous TKI, approximately 60% patients were proven to have T790M. From the above results, this study uses descriptive statistics, and it was set to 120 cases in consideration of feasibility of research.

Study Objectives

Patient characteristics

Patient exclusion criteria

Key inclusion criteria

Key exclusion criteria

Conclusions

Although ctDNA monitoring during the EGFR-TKI treatment is useful, further investigation is necessary to elucidate the efficacy of osimertinib treatment based on the T790M detection in plasma ctDNA.

Acknowledgments

This study was conducted by Comprehensive Support Project For Oncology Research (CSORF) of Public Health Research Foundation. The study fund was provided to CSORF with support from an investigator Sponsored Study Program of AstraZeneca.